Clinical Trials
58 trialsCombination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
M.D. Anderson Cancer Center
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Dana-Farber Cancer Institute
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
University of Virginia
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
National Institutes of Health Clinical Center (CC)
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
Georgetown University
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations
Memorial Sloan Kettering Cancer Center
HTLV-OBS
Assistance Publique - Hôpitaux de Paris
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
ACCESS
Center for International Blood and Marrow Transplant Research
ALPHA2
Allogene Therapeutics
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines
Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies
City of Hope Medical Center
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
Seattle Children's Hospital
Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers
M.D. Anderson Cancer Center
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
GeoVax, Inc.
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors
St. Jude Children's Research Hospital
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Memorial Sloan Kettering Cancer Center
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
Seattle Children's Hospital
Mature B-Cell Lymphoma And Leukemia Study III
St. Jude Children's Research Hospital
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
AB-CliniMACs
Children's Hospital of Philadelphia
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
UNC Lineberger Comprehensive Cancer Center
iFCR
Dana-Farber Cancer Institute
CHARKALL
Baylor College of Medicine
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Children's Oncology Group
ALLCAR19
University College, London
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
Stanford University
EscrimHEMA
University Hospital, Angers
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Integrated Actionable Aging Assessment for Cancer Patients Pilot
University of Colorado, Denver
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Seattle Children's Hospital
CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
Seattle Children's Hospital
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
Seattle Children's Hospital
CarChem
Montreal Heart Institute
INTERACT
Rigshospitalet, Denmark
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
City of Hope Medical Center
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
Genmab
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
Ono Pharmaceutical Co., Ltd.
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
UNC Lineberger Comprehensive Cancer Center